Clinics and Practice (Nov 2022)

Five-Year Retrospective Study of Uterine STUMP and Leiomyosarcoma

  • Madalina Bosoteanu,
  • Mariana Deacu,
  • Raluca Ioana Voda,
  • Cristian Ionut Orasanu,
  • Mariana Aschie,
  • Sabina Elena Vlad,
  • Roxana Cleopatra Penciu,
  • Sergiu Ioachim Chirila

DOI
https://doi.org/10.3390/clinpract12060094
Journal volume & issue
Vol. 12, no. 6
pp. 897 – 907

Abstract

Read online

Taking into account the unpredictable evolution of uterine STUMP and leiomyosarcomas, there are no clearly established therapeutic protocols to date, the only certified treatment being total hysterectomy. We performed a 5-year retrospective study including cases of malignant tumors and those with uncertain malignant potential originating in the smooth muscle tissue of the uterine body. The clinical data, pathological aspects, and the immunohistochemical results were statistically analyzed using SPSS Statistics Version 26. The main associations of the p53 gene were identified with age, atypia, and the occurrence of metastases. The average number of CD8+ T cells correlated with the hormonal status of the patients, the presence of diabetes, and alteration of thyroid function, but also with the severity of the atypia. The therapeutic method was represented by total hysterectomy, and 30% of the patients with leiomyosarcoma also benefited from adjuvant chemotherapy. The average period until death was 25.66 months. The present study showed that the mutant expression of p53 could have a role in assessing the clinical evolution of patients, given the association with exitus and metastasis. In addition, the average number of CD8+ T cells corresponded to severe atypia, indicating the possibility of applying targeted immunotherapies in these cases.

Keywords